Barinthus Biotherapeutics plc. (BRNS) insider trading.
In Q3 2026, insiders at Barinthus Biotherapeutics plc. reported 11 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 9
- Last filed
- 2026-09-11
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Enright William | Director, Officer · Chief Executive Officer | 2 | 0 | 0 |
| Hooftman Leon | Officer · Chief Medical Officer | 2 | 0 | 0 |
| Oxford Science Enterprises plc | Other | 1 | 0 | 0 |
| Dawes Karen A | Director | 1 | 0 | 0 |
| Hammacher Alex | Director | 1 | 0 | 0 |
| Morgon Pierre A. | Director | 1 | 0 | 0 |
| Phillips Anne M. | Director | 1 | 0 | 0 |
| Scheeren Joseph | Director | 1 | 0 | 0 |
| Wright Robin | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-09 | Oxford Science Enterprises plc | U (D) | 8,797,770 | $0.11 | 0 | Form 4/A |
| 2026-09-09 | Dawes Karen A | D (D) | 1,700 | — | 0 | Form 4 |
| 2026-09-09 | Enright William | D (D) | 728,454 | — | 0 | Form 4 |
| 2026-09-09 | Enright William | D (D) | 514,923 | — | 0 | Form 4 |
| 2026-09-09 | Hammacher Alex | D (D) | 3,000 | — | 0 | Form 4 |
| 2026-09-09 | Hooftman Leon | A (A) | 361,530 | — | 361,530 | Form 4 |
| 2026-09-09 | Hooftman Leon | D (D) | 361,530 | — | 0 | Form 4 |
| 2026-09-09 | Morgon Pierre A. | D (D) | 10,506 | — | 0 | Form 4 |
| 2026-09-09 | Phillips Anne M. | D (D) | 3,000 | — | 0 | Form 4 |
| 2026-09-09 | Scheeren Joseph | D (D) | 23,000 | — | 0 | Form 4 |
| 2026-09-09 | Wright Robin | D (D) | 48,256 | — | 0 | Form 4 |
Transaction codes in this quarter
Get BRNS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1828185&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · Barinthus Biotherapeutics plc. on SEC.gov
Questions
Are insiders buying or selling Barinthus Biotherapeutics plc. (BRNS)?
In Q3 2026, insiders at Barinthus Biotherapeutics plc. reported 11 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Barinthus Biotherapeutics plc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/brns.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.